Heart Failure Drugs Market

The global Heart Failure Drugs Market is valued at USD 8.6 Billion in 2024 and is projected to reach a value of USD 21.4 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 12.1% between 2025 and 2035.

Premium Insights

The Heart Failure Drugs market is driven by increase in the rate of cardiovascular cases and the growing geriatric population globally. The increase in the need for heart failure drugs as they treat different symptoms of the disorder and the patient's dependency on them fuels the market growth. The change in lifestyle, such as excessive alcohol consumption, smoking, and unhealthy diet habits, causes heart problems propelling the Heart Failure Drugs market growth. The increase in investment by key players and the increase in research and development activities influence the Heart Failure Drugs market industry.

Key Highlights

• In 2024, based on the Drugs Type, the ACE Inhibitors category accounted largest share in Heart Failure Drugs market industry
• In 2024, based on the End User, the Hospitals category accounted for significant market share of 56.70% in Heart Failure Drugs market
• North America dominated the Heart Failure Drugs market industry with largest market share of 36.20% in 2024
• Europe region is anticipated to grow at the highest CAGR during the forecast period

Drugs Type Overview

The Drugs type segment is divided into Beta-Blockers, ACE Inhibitors, Angiotensin, Receptor Neprilysin Inhibitors, Angiotensin Receptor Blockers, Diuretic. The ACE Inhibitors segment held the largest share of the Heart Failure Drugs market industry.

• ACE inhibitors (Angiotensin-Converting Enzyme inhibitors) are mainly used in the treatment of heart failure. ACE inhibitors decreases the formation of angiotensin II, thereby decreasing both arteriolar and venous resistance. ACE inhibitors (Angiotensin-Converting Enzyme inhibitors) are widely used to manage heart failure by relaxing blood vessels, reducing blood pressure, and improving blood flow, which decreases the workload on the heart. Growing rates of heart failure and the growing use of combination treatments containing ACE inhibitors are the main factors propelling the segment's expansion.
• Beta-blockers are a critical segment in the Heart Failure Drugs market industry, widely fix to manage chronic heart failure by reducing the workload on the heart and improving its efficiency. Beta-blockers drugs are carvedilol, metoprolol succinate, and bisoprolol are commonly used in combination with other heart failure therapies like ACE inhibitors or diuretics. The Beta-blocker segment is primarily driven by an aging population, increasing prevalence of cardiovascular diseases, and greater awareness of heart failure management protocols
• The angiotensin segment, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), plays a critical role in the Heart Failure Drugs market industry. These angiotensin medications improve blood flow, reduce fluid retention, and enhance heart efficiency, making them a cornerstone in heart failure treatment. The segment steadily grows due to their proven efficacy, evolving clinical guidelines, and increasing prevalence of heart failure worldwide
• The Receptor Neprilysin Inhibitors segment growth is driven by increasing prevalence of heart failure, expanding clinical indications, and rising awareness among healthcare providers about the benefits of these inhibitors over traditional treatments. Continuous R&D efforts to develop next-generation neprilysin inhibitors and their potential combination with other therapies further highlight this segment's importance in the Heart Failure Drugs market industry
• The Angiotensin Receptor Blockers segment growth is fueled by increasing prevalence of heart failure, especially among aging populations, and rising awareness of effective treatment options. Additionally, clinical advancements and the introduction of combination therapies involving ARBs (e.g., ARB and neprilysin inhibitors) enhance their therapeutic efficacy, contributing to Heart Failure Drugs market industry
• The diuretic segment plays an important role in the Heart Failure Drugs market, focusing on medications that help remove excess fluid and sodium from the body to reduce symptoms like swelling and breathlessness. Diuretics are often used as part of combination therapy in managing heart failure, addressing fluid retention while complementing other drugs that target the underlying cardiac dysfunction

End Use Overview

The End Use segment is divided into hospitals, Specialty center, and others. The hospitals segment held the largest share of 56.70% in the Heart Failure Drugs market industry.

The hospitals segment growth is driven by the presence of specialized cardiology departments and intensive care units (ICUs) in hospitals is addressing complex cases and driving demand for Heart Failure Drugs industry. Moreover, hospitals often initiate long-term medication regimens for chronic heart failure, including beta-blockers, ACE inhibitors, and SGLT2 inhibitors, ensuring continuity of care post-discharge. Additionally, Hospitals are equipped with advanced diagnostic and treatment facilities, enabling healthcare providers to assess the severity of heart failure and tailor treatment plans, including the use of intravenous (IV) medications like diuretics and vasodilators for acute decompensated heart failure.

In the Heart Failure Drugs market, specialty centers represent a fastest growing segment in the forecast period, and focused on delivering advanced, tailored care to patients with complex heart failure conditions. Specialty centers play a critical role in managing severe cases, particularly for patients requiring frequent monitoring or advanced treatments like implantable devices or combination drug therapies.

Regional Overview

In 2024, the Heart Failure Drugs market size of the North America is USD 3.11 Billion.

North America Heart Failure Drugs market industry is driven by a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and strong adoption of innovative therapies. For instance, in February 2023, Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. The label also states LVEF is a variable measure and clinical judgment should be used in deciding whom to treat. Furthermore, in region, rising geriatric population, which is more prone to heart failure, coupled with increasing awareness about early diagnosis and treatment, further propels Heart Failure Drugs market growth.

U.S. Heart Failure Drugs Market Analysis

The U.S. Heart Failure Drugs market size valued at USD 2.4 Billion in 2024 to USD 8.3 Billion in 2035, is anticipated to grow at a CAGR of 16.8% from 2025 to 2035. The U.S. market is driven by increasing prevalence of heart failure, the aging population, advancements in drug therapies, rising awareness and diagnosis, and supportive government initiatives. The presence of major key players such as Novartis AG, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Merck & Co., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Bayer AG, GlaxoSmithKline plc and Amgen. These companies have taken a clinical trials and pharmaceutical innovations, with leading companies focusing on developing targeted therapies and combination drug formulations.

Europe Heart Failure Drugs Market Analysis

The Europe Heart Failure Drugs market size is expected to account for a substantial share driven by factors such as the region's aging population, increasing prevalence of cardiovascular diseases, and significant advancements in treatment options. Additionally, the regulatory environment in Europe, including the European Medicines Agency (EMA), plays a crucial role in accelerating the approval and availability of new drugs for health failure. The market is further supported by ongoing research and clinical trials, along with growing awareness of heart failure management among healthcare providers and patients.

Heart Failure Drugs Market Industry Trends

1. Increasing Prevalence of Heart Failure: Rising cases due to aging populations, lifestyle factors, and comorbid conditions such as hypertension and diabetes
2. Advancements in Drug Development: Focus on novel therapies, including SGLT2 inhibitors, ARNI (angiotensin receptor-neprilysin inhibitors), and personalized treatment approaches
3. Adoption of Combination Therapies: Increased use of drug combinations to improve patient outcomes and manage multiple aspects of heart failure
4. Minimally Invasive Treatment Options: Growth in minimally invasive procedures alongside drug therapies for better management of heart failure
5. Rising Adoption of Remote Patient Monitoring: Use of wearable devices and telemedicine to monitor patients, improving early detection and treatment compliance

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing Prevalence of Heart Failure

The increasing prevalence of heart failure is a significant driver in the Heart Failure Drugs market industry, as it leads to a higher demand for effective treatments. The global rise in heart failure cases can be attributed to various factors, such as an aging population, lifestyle-related risk factors (including obesity, hypertension, and diabetes), and the growing incidence of cardiovascular diseases. As people age, the heart becomes more vulnerable to conditions like heart failure, creating a larger patient pool that requires continuous management through pharmacological interventions. Additionally, the prevalence of comorbidities such as diabetes and high blood pressure further exacerbates heart failure, leading to a greater need for specialized drugs. The rising burden of heart failure is prompting healthcare systems worldwide to invest in better management and treatment strategies, which includes the development and adoption of novel drug therapies. This growing patient population, coupled with increased awareness and better diagnosis, is drives the demand for heart failure drugs.

Rising Awareness and Early Diagnosis

Rising awareness and early diagnosis are key drivers, as they contribute to improved patient outcomes and a higher demand for effective treatments. Increased public and healthcare professional awareness about heart failure symptoms, risk factors, and the importance of early intervention has led to earlier detection of the condition. Early diagnosis enables timely initiation of therapies, preventing disease progression and improving long-term health outcomes. With the growing availability of diagnostic tools, such as biomarkers and imaging technologies, healthcare providers can now identify heart failure at earlier stages, even before symptoms become severe. Moreover, public health campaigns and educational initiatives have raised awareness about lifestyle modifications, further encouraging individuals to seek medical help sooner.

Competitive Landscape

The Heart Failure Drugs market report is characterized by the presence of both established players and emerging companies, each strive for market share through product innovation, strategic partnerships, and geographic expansion. Industry giants like Amgen, Astrazeneca, Bayer AG, Novartis AG, Gilead, Pfizer Inc, Teva Pharmaceuticals, Cardior Pharmaceuticals GmbH, GlaxoSmithKline, Bristol-Myers Squibb Company, Eli Lilly and Company. These companies are investing heavily in research and development to introduce new drugs that target different mechanisms of heart failure, including drugs that address heart failure with preserved ejection fraction (HFpEF), a form of the disease that has historically lacked effective treatments. Moreover, regulatory bodies like the FDA and EMA are key factors influencing the competitive landscape, with companies rushing to meet approval requirements to gain market access for their innovative therapies.

The key players in the global Heart Failure Drugs market industry report include - Amgen, Astrazeneca, Bayer AG, Novartis AG, Gilead, Pfizer Inc, Teva Pharmaceuticals, Cardior Pharmaceuticals GmbH, GlaxoSmithKline, Bristol-Myers Squibb Company, Eli Lilly and Company among others.

Recent Market Developments

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

• In January 2023, AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease

Bayer launches novel heart failure drug Verquvo for Rs 127 a pill

• In September 2022, Bayer launched a novel heart failure drug in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It’s a one pill a day therapy. The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalisation among worsening heart failure patients, the company said

The global Heart Failure Drugs market can be categorized as Drug Type, End User, and Region.